{"filings":[{"id":499476,"accession_number":"0001437749-26-017612","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-05-18T20:17:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q1 revenue up 200% to $432K; net loss cut to $1.7M; Flyte acquisition adds aviation revenue","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $432K (200% YoY) driven by medical device segment (+73%) and new Flyte aviation platform.","Net loss narrowed to $1.7M from $4.0M in Q1 2025; includes ~$560K non-cash charges.","Flyte acquisition generated $200K monthly revenue run rate within 22 days; fleet expanding to 5 jets by end of Q2 2026.","Medical device products in 15 countries; new clinical data on VIVO and LockeT presented at HRS congress.","Company now a dual-engine growth platform combining medical devices and aviation infrastructure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":432000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94941,"accession_number":"0001437749-26-013183","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision closes $3.47M Series C-2 preferred; issues $11M Series D for Flyte acquisition","event_type":"other_material","confidence":"high","bullets":["3,470 shares of Series C-2 Preferred at $1,000 stated value sold for gross proceeds of $3,470,000.","11,028 shares of Series D Preferred ($11.03M stated value) issued to SEG Jets and Creatd for Fly Flyte acquisition.","Series C-2 conversion price $0.883/share, floor $0.35; Series D conversion price $1.1038/share, subject to reduction.","Stockholder approval obtained April 15, 2026; proceeds for working capital and general corporate purposes.","Beneficial ownership limitation initially 4.99%, can be increased to 9.99% on 61 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94940,"accession_number":"0001437749-26-012393","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Catheter Precision shareholders approve reverse split (1:2-1:100) and preferred share issuances","event_type":"other_material","confidence":"high","bullets":["All six proposals passed at April 15 special meeting; 49.5% of outstanding shares voted.","Reverse stock split authorized at ratio between 1-for-2 and 1-for-100, at board's discretion.","Issuance of common stock underlying Series C-1, C-2, C-3, C-4 convertible preferred approved (690,693 for).","Issuance of shares underlying Series D and Series J convertible preferred also approved (~690,600 votes for each).","Approval of conversion price reduction for Series B convertible preferred stock (690,825 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107679,"accession_number":"0001437749-26-010721","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision FY2025 rev +95% to $819K; net loss $17.2M; acquires Flyte aviation platform","event_type":"earnings","confidence":"high","bullets":["Revenue $819K in FY2025, up 95% from $420K in FY2024; gross margin improved to 92.3% from 90.0%.","Net loss of $17.2M in FY2025, of which $7.8M non-cash, compared to $16.6M net loss in FY2024.","Q4 2025 revenue $238K, up 60% YoY; net loss $5.3M ($3.5M non-cash) vs $5.6M in Q4 2024.","Acquired Flyte, a regional air mobility company, post-year-end; financing completed to support two-platform growth strategy.","CE Mark received for LockeT in April 2025; added 32 new customers across VIVO and LockeT platforms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107678,"accession_number":"0001437749-26-007380","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision acquires 80% of Fly Flyte and Ponderosa Air for $11.6M; raises up to $39M in PIPE","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of 80.02% of Fly Flyte, Inc. and 100% of Ponderosa Air from Creatd for $11.55M in cash and Series D preferred stock.","Private placement of Series C convertible preferred stock raises $1.85M at first close, potential additional raises up to $35.6M.","Proceeds used for restructuring legacy catheter business, potential sale of medical devices, and reducing cash burn.","Conversion prices start at $1.43, adjust to 80% of market with $0.35 floor, subject to stockholder approval.","Registration rights agreement filed to register resale of conversion shares within 30–60 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107677,"accession_number":"0001437749-26-003940","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Catheter Precision secures up to $36.5M institutional financing; converts $9M liabilities into equity","event_type":"other_material","confidence":"high","bullets":["CEO David Jenkins exchanged royalty rights for ~9,490 shares of Series J Preferred Stock convertible into 6,083,005 common shares at $1.56, subject to stockholder approval.","ATM equity offering program terminated; no future equity lines or forward-priced agreements anticipated.","Short-term notes converted to long-term debt with maturities of 2-3 years.","Additional $9M in short and long-term liabilities converted into equity, strengthening balance sheet.","Up to $36.5M in institutional financing secured to expand market presence and advance growth initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107676,"accession_number":"0001437749-26-003387","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Catheter Precision raises $2.18M in private placement, acquires 19.98% stake in FLYTE for $5.25M","event_type":"m_and_a","confidence":"high","bullets":["Initial closing of private placement yields $2.18M; additional closings could raise up to ~$44.6M total.","Issues Series C-1 convertible preferred at $1.43/share; conversion price can reset to 80% of market price after stockholder approval.","Acquires 19.98% of Fly Flyte, Inc. (air-mobility) for $5.25M in Series D convertible preferred, contingent on stockholder approval.","Existing Series B preferred and warrants repriced to $1.78, generating $400k cash from warrant exercises.","Proceeds to repay debt, wind down legacy catheter business, and explore going-private or spin-off transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107675,"accession_number":"0001437749-26-000839","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Catheter Precision extends maturity of $1.5M in 8% promissory notes to 2028-2029","event_type":"debt","confidence":"high","bullets":["Extended $500k note from CEO David A. Jenkins matured Jan 31, 2026, now due Jan 31, 2029.","Extended three FatBoy Capital notes totaling $500k from Jan 31, 2026, to Jan 31, 2029.","Extended Jenkins Family Charitable Institute $500k note from Jan 31, 2026, to Jan 31, 2028.","All notes carry 8% interest; amendments dated Dec 31, 2025, and effective same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124049,"accession_number":"0001437749-25-036000","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Catheter Precision terminates ATM equity facility after selling ~$4.0M of $4.3M","event_type":"other_material","confidence":"high","bullets":["Terminated ATM agreement with Ladenburg Thalmann effective November 24, 2025; no penalties.","Prior to termination, $4.0M of common stock sold under the $4.3M capacity.","Remaining $0.3M of at-the-market offering capacity is no longer available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124048,"accession_number":"0001437749-25-035245","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q3 revenue up 135% to $226K; net loss down 45% to $2.25M","event_type":"earnings","confidence":"high","bullets":["Total revenue Q3 2025: $226K, +135% YoY from $96K; nine-month revenue $581K, +114%.","GAAP net loss Q3 2025: $2.25M, 45% reduction from $4.12M in Q3 2024.","Nine-month net loss $11.4M vs $11.0M; non-cash charges $4.2M.","CE Mark approval for LockeT driving international interest; reorders in South Africa and first French VIVO order.","VIVO clinical studies completed in 2025; CEO expects major US and international expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":581000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124047,"accession_number":"0001437749-25-031036","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve increase in authorized shares to 500M for Catheter Precision","event_type":"other_material","confidence":"high","bullets":["Special meeting on Oct 10, 2025 had 43.1% quorum (641,616 of 1,487,266 shares outstanding).","Proposal 1: authorized common shares increased from 60M to 500M (497,162 for, 133,882 against).","Proposal 2: WithumSmith+Brown ratified as independent auditor for FY2026 (610,134 for).","Proposal 3: approval to adjourn meeting if needed passed (514,362 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140726,"accession_number":"0001437749-25-027270","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision secures UK approval for LockeT; partners with distributor HC21","event_type":"regulatory","confidence":"high","bullets":["LockeT suture retention device approved for commercialization in the UK; received CE Mark in May 2025.","Exclusive distribution agreement with HC21 (€180M revenue, 500+ employees across UK and Ireland).","LockeT aims to enhance patient comfort, enable earlier discharge, and help NHS reduce waiting lists.","Fatih Ayoglu (Sales Manager EMEA & APAC) highlighted potential to free up hospital capacity and accelerate patient throughput."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140725,"accession_number":"0001437749-25-027153","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Catheter Precision effects 1-for-19 reverse stock split effective August 15, 2025","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio of 1-for-19; effective 12:01 a.m. ET on August 15, 2025.","Outstanding shares reduced from ~23,327,516 to ~1,227,764; no change to authorized shares (60M common).","Stock continues trading under symbol VTAK with new CUSIP 74933X 708; no fractional shares issued.","Proportionate adjustments made to per-share exercise prices and shares underlying outstanding options, warrants, and preferred stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140724,"accession_number":"0001437749-25-025935","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q2 revenue up 128% YoY to $212K; net loss $5.4M with $3.2M non-cash","event_type":"earnings","confidence":"high","bullets":["Revenue $212K for Q2 2025 vs $93K in Q2 2024, 128% increase; sequential growth 48%.","Net loss $5.4M for Q2 includes $3.2M non-cash charges; cash $838K at June 30.","Received CE Mark for LockeT product; European sales expected to start in Q3 2025.","Completed acquisition of Cardionomic heart failure assets via 82%-owned subsidiary Cardionomix.","Formed Kardionav JV for implant-based software to locate ventricular tachycardia ablation sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":355000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140723,"accession_number":"0001437749-25-023654","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Catheter Precision announces 1-for-19 reverse stock split effective August 15, 2025","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-19 approved by board after shareholder authorization at July 25 annual meeting.","Pre-split shares reduced from ~23.3M to ~1.2M; no fractional shares issued, cash paid instead.","Split intended to maintain NYSE American minimum bid price requirement; CUSIP changes to 74933X708.","Annual meeting also approved issuance of up to 4.29M shares upon Series L warrant exercise and up to 8.57M shares on Series B preferred conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158462,"accession_number":"0001437749-25-020251","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision sees record Q2 LockeT sales; Italy distributor secured","event_type":"other_material","confidence":"high","bullets":["Q2 2025 LockeT sales on track to be highest to date, outpacing Q2 2024 by more than $84,000.","Three hospitals — Montefiore, Eisenhower Health, Overland Park Regional — expected to issue >$100K in purchase orders each by end of 2025.","Secured new distributor in Italy; anticipates additional distributors in Spain, Portugal, and UK.","Live case scheduled June 16 with a key opinion leader at an Italian symposium to increase market awareness.","CEO cites expanded existing customer usage and European expansion as drivers of revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158461,"accession_number":"0001437749-25-019768","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Catheter Precision Board approves warrant to Ladenburg Thalmann for 257,143 shares at $0.5424","event_type":"other_material","confidence":"high","bullets":["Warrant issued to Ladenburg Thalmann as partial compensation for pipe financing closed May 12, 2025.","Exercise requires stockholder approval at annual meeting on July 25, 2025; warrant expires June 6, 2030.","Warrant and underlying shares are unregistered under the Securities Act of 1933."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158460,"accession_number":"0001437749-25-019731","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Catheter Precision terminates Chief Commercial Officer; CEO assumes role temporarily","event_type":"leadership","confidence":"high","bullets":["Marie-Claude Jacques' employment as CCO discontinued effective June 2, 2025.","CEO David Jenkins will serve as interim CCO until a replacement is hired.","No further details on reason for departure or timeline for search provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158459,"accession_number":"0001437749-25-018985","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Catheter Precision details pro forma dilution to new investors at $1.25/share in ATM offering","event_type":"other_material","confidence":"high","bullets":["Historical net tangible book value as of Mar 31, 2025: $(15.8)M or $(1.71)/share; after offering: $(14.6)M or $(0.95)/share.","ATM offering assumes 4,333,333 shares at $0.30/share (May 14 close), net proceeds $1.2M; dilution to new investors $(1.25)/share.","Pro forma adjustments include 1,748,666 shares issued in April 2025; total outstanding after offering ~15.4M shares.","As of Mar 31, 2025, 17.4M warrants (weighted avg exercise $2.20) and 2.2M options outstanding represent additional dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158458,"accession_number":"0001437749-25-017634","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Catheter Precision enters ATM agreement to sell up to $1.3M of common stock","event_type":"other_material","confidence":"high","bullets":["ATM agreement with Ladenburg Thalmann allows sale of up to $1.3M of common stock on NYSE American.","Proceeds will be used for operations and working capital; company has no obligation to sell any shares.","Ladenburg receives 3.0% commission on gross proceeds; agreement ends upon sale of all shares or by 5-day notice.","Shares are issued under existing S-3 registration statement (File No. 333-284217) effective Jan 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158457,"accession_number":"0001437749-25-017616","cik":1716621,"company_name":"Catheter Precision, Inc.","ticker":"VTAK","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Catheter Precision Q1 revenue up 74% to $143K, net loss $4.0M; cash $450K","event_type":"earnings","confidence":"high","bullets":["Revenue $143K vs $82K YoY (+74%); net loss $4.0M including $1.2M non-cash charges.","Cash $450K at March 31; after quarter end secured $1.5M private placement from institutional investors.","Acquired Cardionomics assets via 82%-owned subsidiary Cardionomix, including CPNS system for ADHF.","Acquired PeriKard, LLC (pericardial access kit); first U.S. patent allowed for LockeT device.","Clinical data presented at HRS 2025: VIVO 94% accurate, LockeT safe/effective in 139-patient study."],"consensus_eps_estimate":-3.876,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":143000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}